[1]仇晓霞,金光鑫,郭 艳,等.肿瘤患者上臂植入输液港并发上肢静脉血栓发生率及危险因素 [J].介入放射学杂志,2019,28(03):242-246.
 QIU Xiaoxia,JIN Guangxin,GUO Yan,et al.The incidence of venous thrombosis related to totally implantable access port in upper arm in cancer patients and its risk factors[J].journal interventional radiology,2019,28(03):242-246.
点击复制

肿瘤患者上臂植入输液港并发上肢静脉血栓发生率及危险因素

()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
28
期数:
2019年03期
页码:
242-246
栏目:
肿瘤介入
出版日期:
2019-03-25

文章信息/Info

Title:
The incidence of venous thrombosis related to totally implantable access port in upper arm in cancer patients and its risk factors
作者:
仇晓霞 金光鑫 郭 艳 张学彬 刘丽娟
Author(s):
QIU Xiaoxia JIN Guangxin GUO Yan ZHANG Xuebin LIU Lijuan.
Faculty of Health Service, Naval Medical University, Shanghai 200433, China
关键词:
【关键词】 输液港上臂 肿瘤患者 上肢静脉血栓
文献标志码:
A
摘要:
【摘要】 目的 探讨肿瘤患者上臂完全植入式输液港(TIAP)并发上肢静脉血栓(UEVT)发生率及危险因素。方法 收集 2014年2月至2018年4月接受上臂植入TIAP行化疗的1 724例患者临床资料,对患者一般资料、置管情况、病情进展情况及UEVT发生率进行分析,采用单因素和多因素logistic回归分析来确定症状性血栓相关危险因素。结果 共17例患者出现症状性UEVT,发生率为0.99%(17/1 724)。上臂TIAP植入后至血栓确诊的时间平均为55.6 d(2~334 d)。单因素分析中,感染(P<0.01)和导管继发异位(P<0.01)与UEVT风险显著相关。多变量二元回归分析结果显示感染(RR=16.85,P<0.01)和导管继发异位(RR=101.09,P<0.01)是上臂TIAP相关UEVT的2个重要独立预测因子。结论 感染和导管继发异位是引起上臂TIAP相关血栓形成的独立危险因素。

参考文献/References:

[1] 中心静脉通路上海协作组. 完全植人式输液港上海专家共识[J]. 介入放射学杂志, 2015, 24: 1029- 1033.
[2] Gonda SJ, Li R. Principles of subcutaneous port placement[J]. Tech Vasc Intervent Rad, 2011, 14: 198- 203.
[3] Teichgraber U, Nagel SN, Kausche S. Evaluation of correlations between underlying disease and port complications[J]. Rofo. 2014, 186: 496- 500.
[4] 徐海萍, 周 琴, 韩 伟, 等. 手臂输液港与胸壁输液港常见并发症的meta分析[J]. 中华护理杂志, 2018, 53: 368- 374.
[5] 黄琬玲, 周燕斌. 肺癌高凝状态的发生机制及治疗对策的新认识[J]. 国际呼吸杂志, 2010, 30: 237- 242.
[6] Almasi- Sperling V, Hieber S, Lermann J, et al. Femoral placement of totally Implantable venous access ports in patients with bilateral breast cancer[J]. Geburtshilfe Frauenheilkd, 2016, 76: 53- 58.
[7] Wildgruber M, Borgmeyer S, Haller B, et al. Short- term and long- term outcome of radiological- guided insertion of central venous access port devices implanted at the forearm: a retrospective monocenter analysis in 1704 patients[J]. Eur Radiol, 2015, 25: 606- 616.
[8] Infusion Nurses Society. Infusion therapy standards of practice[J]. J Infus Nurs, 2016, 39(Suppl 1): S1- S139.
[9] Vescia S, Baumgartner AK, Jacobs VR, et al. Management of venous port systems in oncology: a review of current evidence[J]. Ann Oncol, 2008, 19: 9- 15.
[10] Marcy PY, Chamorey E, Amoretti N, et al. A comparison between distal and proximal port device insertion in head and neck cancer[J]. Eur J Surg Oncol, 2008, 34: 1262- 1269.
[11] Goltz JP, Schmid JS, Ritter CO, et al. Identification of risk factors for catheter- related thrombosis in patients with totally implantable venous access ports in the forearm[J]. J Vasc Access, 2012, 13: 79- 85.
[12] Kuriakose P, Colon- Otero G, Paz- Fumagalli R. Risk of deep venous thrombosis associated with chest versus arm central venous subcutaneous port catheters: a 5- year single- institution retrospective study[J]. J Vasc Interv Radiol, 2002, 13: 179- 184.
[13] Tesselaar ME, Ouwerkerk MA, Nooy MA, et al. Risk for catheter- related thrombosis in cancer patients[J]. Eur J Cancer, 2004, 40: 2253- 2259.
[14] David L, Nuria FH, Ashwini C, et al. Management of infections related to totally implantable venous- access ports: challenges and perspectives[J]. Lancet Infect Dis, 2014, 14: 146- 159.
[15] Piran S, Ngo V, McDiarmid S, et al. Incidence andrisk factors of symptomatic venous thromboembolism related to implanted ports in cancer patients[J]. Thromb Res, 2014, 133: 30- 33.
[16] Abdullah BJ, Mohammad N, Sangkar JV, et al. Incidence of upper limb venous thrombosis associated with peripherally inserted central catheters(PICC)[J]. Br J Radiol, 2005, 78: 596- 600.
[17] Allen AW, Megargell JL, Brown DB, et al. Venous thrombosis associated with the placement of peripherally inserted central catheters[J]. J Vasc Interv Radiol, 2000, 11: 1309- 1314.
[18] Tran H, Arellano M, Chamsuddin A, et al. Deep venous thromboses in patients with hematological malignancies after peripherally inserted central venous catheters[J]. Leuk Lymphoma, 2010, 51: 1473- 1477.
[19] Sharp R, Cummings M, Fielder A, et al. The catheter to vein ratio and rates of symptomatic venous thromboembolism in patients with a peripherally inserted central catheter(PICC): a prospective cohort study[J]. Int J Nurs Stud, 2015, 52: 677- 685.
[20] Del Principe MI, Buccisano F, Maurillo L, et al. Infections increase the risk of central venous catheter- related thrombosis in adult acute myeloid leukemia[J]. Thromb Res, 2013, 132: 511- 514.
[21] Qiu XX, Guo Y, Fan HB, et al. Incidence, risk factors and clinical outcomes of peripherally inserted central catheter spontaneous dislodgment in oncology patients: a prospective cohort study[J]. Int J Nurs Stud, 2014, 51: 955- 963.
[22] Jacobs W, Zaroukian M. Coughing and central venous catheter dislodgement[J]. JPEN J Parent Ent Nutr, 1991, 15: 491- 493.
[23] Cardella JF, Cardella K, Bacci N, et al. Cumulative experience with 1273 peripherally inserted central catheters at a single institution[J]. J Vasc Interv Radiol, 1996, 7: 5- 13.
[24] Kearon C, Akl EA, Comerota AJ. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention guidlines[J]. Chest, 2012, 142: 1698- 1704.
[25] Zochios V, Umar I, Simpson N, et al. Peripherally inserted central catheter(PICC)- related thrombosis in critically ill patients[J]. J Vasc Access, 2014, 15: 329- 337.
[26] Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence- based clinical practice guidelines[J]. Chest, 2012, 141(2 Suppl): e195S- e226S.
[27] Ahn DH, Illum HB, Wang DH, et al. Upper extremity venous thrombosis in patients with cancer with peripherally inserted central venous catheters: a retrospective analysis of risk factors[J]. J Oncol Pract, 2013, 9: e8- e12.
[28] 仇晓霞, 金光鑫, 郭 艳, 等. 超声导引下上臂完全植入式输液港植入临床应用[J]. 介入放射学杂志, 2017, 26: 689- 694.

相似文献/References:

[1]杜 鹏,倪才方,樊宝瑞,等.经颈内静脉植入式输液港导管长度的估算方法[J].介入放射学杂志,2019,28(02):124.
 DU Peng,NI Caifang,FAN Baorui,et al.The method for estimating the catheter length of implantable access port via internal jugular vein[J].journal interventional radiology,2019,28(03):124.
[2]杜鹏,倪才方,樊宝瑞,等.立位时静脉输液港港体位置变化及影响因素分析[J].介入放射学杂志,2020,29(03):288.
 DU Peng,NI Caifang,FAN Baorui,et al.The changing of port body position of TIAP in patient’s erect position and analysis of its influencing factors[J].journal interventional radiology,2020,29(03):288.
[3]上海市医学会肿瘤内科专科分会,长三角肿瘤专科联盟.上臂完全植入式静脉给药装置临床应用专家共识(2022版)[J].介入放射学杂志,2023,32(01):2.
 Oncology Chapter of Shanghai Medical Association,League of Oncology of Yangte River Delta Region.Expert consensus on the clinical application of totally implantable venous access devices in the upper arm (2022 Edition)[J].journal interventional radiology,2023,32(03):2.

备注/Memo

备注/Memo:
(收稿日期:2018-09-19)
(本文编辑:俞瑞纲)
更新日期/Last Update: 2019-03-20